Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | RECQL | P46063 | 3/20 | 0.70 |
| ▸ | APEX1 | P27695 | 3/20 | 0.70 |
| ▸ | THPO | P40225 | 3/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | DRD1 | P21728 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 2/20 | 0.70 |
| ▸ | DRD5 | P21918 | 2/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL31147982 | 0.88 | KDM4E (0.84) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL28995038 | 0.88 | KDM4E (0.84) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL30355306 | 0.88 | KDM4E (0.84) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL5441164 | 0.86 | KDM4E (0.81) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL3122743 | 0.86 | CA2 (0.53) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL11668670 | 0.84 | KDM4E (0.78) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL29245423 | 0.84 | KDM4E (0.78) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL9051903 | 0.84 | KDM4E (0.84) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL21990790 | 0.84 | TAAR1 (0.91) | KDM4EMAPTTDP1MAPK1HSD17B10 | |
| Dopamine SCHEMBL9166387 | 0.84 | KDM4E (1.00) | KDM4EMAPTTDP1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322616-A2 | QUINOLINE-(C=O)-(DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002018341-A9 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYST PROD INC (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | MP BIOMEDICALS, LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | CASP3, CASP1, BAX | KDM4E 1714/4885MAPT 764/4885TDP1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.